In phase 3 clinical trials, radiation in combination with the EGFR inhibitor cetuximab has been proved to achieve a survival benefit of 10% in head and neck squamous cell carcinoma (HNSCC)24. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.